Plavix (Clopidogrel) Shortage: What Providers and Prescribers Need to Know in 2026

Clopidogrel (Plavix) is not currently listed as a shortage drug by the FDA in 2026 — and for most of your patients taking the 75 mg maintenance dose, supply is not an issue. However, providers in cardiology, neurology, primary care, and vascular medicine should be aware of the nuanced supply landscape for this critical antiplatelet agent. Patients who run out of clopidogrel — particularly those with recent coronary stents or high cardiovascular risk — face immediate, life-threatening risk from premature discontinuation.

This article provides a clinical summary for prescribers: current supply status, CYP2C19 considerations, FDA guidance, therapeutic substitution options, and practical strategies for keeping your highest-risk patients on therapy.

Current Supply and Shortage Status (2026)

Generic clopidogrel 75 mg is manufactured by multiple companies — including Apotex, Aurobindo, Dr. Reddy's, Teva, and others — and is widely stocked at pharmacies nationwide. No FDA shortage is active as of 2026. The 75 mg maintenance formulation is reliably available at all major chain pharmacies (Walmart, CVS, Walgreens, Costco, Kroger) and most independent pharmacies.

The 300 mg loading dose tablet is a different story. Community pharmacies often do not stock this formulation, which is primarily used in acute or peri-procedural settings. When patients are discharged from a cardiac procedure with a 300 mg prescription, they may encounter difficulty finding it at their neighborhood pharmacy. Providers should anticipate this when discharging patients and either provide samples, route the patient to a hospital-connected pharmacy, or coordinate a same-day fill.

CYP2C19 Pharmacogenomics: The FDA Boxed Warning

Clopidogrel carries a boxed warning from the FDA regarding CYP2C19 poor metabolizer status. Clopidogrel is a prodrug requiring hepatic conversion by CYP2C19 to its active thiol metabolite. Patients who are CYP2C19 poor metabolizers (PM) — approximately 2-14% of the general population, and 50%+ in some East Asian populations — have significantly diminished antiplatelet response and higher rates of adverse cardiovascular events post-MI.

CYP2C19 genotyping is commercially available (e.g., GeneSight, Genomind, Veracuity) and is increasingly used in post-ACS and post-PCI settings. The 2022 Clinical Pharmacogenomics Implementation Consortium (CPIC) guidelines recommend considering an alternative P2Y12 inhibitor (ticagrelor or prasugrel) in CYP2C19 poor or intermediate metabolizers, particularly in ACS or PCI settings.

Additionally, the 2024 ACC/AHA Peripheral Artery Disease guidelines recommend clopidogrel as a first-line single antiplatelet agent for symptomatic PAD — reinforcing its continued importance in the cardiovascular armamentarium.

Key Drug Interactions Providers Must Monitor

Several clinically significant drug interactions may reduce clopidogrel's efficacy or increase bleeding risk:

• Omeprazole and Esomeprazole (Prilosec, Nexium): These PPIs are CYP2C19 inhibitors and significantly reduce the systemic exposure to clopidogrel's active metabolite. The FDA advises against co-administration. Prefer pantoprazole, dexlansoprazole, or rabeprazole in patients who need acid suppression on clopidogrel.
• Repaglinide: The acyl-glucuronide metabolite of clopidogrel is a strong CYP2C8 inhibitor, increasing repaglinide exposure 3.9-5.1x. Avoid concurrent use or initiate repaglinide at 0.5 mg/meal with close glucose monitoring.
• NSAIDs, warfarin, SSRIs/SNRIs: All increase bleeding risk. Evaluate each addition to a clopidogrel regimen carefully, especially in older patients.
• Opioids (morphine): Decrease the Cmax and AUC of clopidogrel's active metabolite by approximately 34% via delayed gastric emptying. Consider parenteral antiplatelet agents in opioid-treated ACS patients if rapid and reliable platelet inhibition is required.

Therapeutic Substitution Options When Clopidogrel Is Unavailable

If a patient with a recent coronary stent cannot access clopidogrel, the most evidence-supported alternatives are:

• Ticagrelor (Brilinta) 90 mg BID: Superior to clopidogrel in reducing CV death, MI, and stroke in ACS (PLATO trial). Does not require CYP2C19 activation. Reversible binding. Disadvantage: twice-daily dosing, dyspnea risk (~14% of patients), higher bleeding risk. Generic ticagrelor available since 2024.
• Prasugrel (Effient) 10 mg QD: Preferred in high-thrombotic risk PCI patients without prior stroke/TIA, low body weight (<60 kg), or age ≥75. More potent, once-daily, less CYP2C19 dependent. Significantly higher bleeding risk — not appropriate for patients with prior stroke/TIA.

37,770+ patients found their medications in stock

37K+

Find Plavix In Stock Today →

Practical Strategies to Prevent Dangerous Gaps in Therapy

1. Educate patients at discharge: Emphasize in plain language that stopping clopidogrel without guidance can be fatal. Patients often don't understand the urgency.
2. Confirm pharmacy availability before discharge: Send the prescription electronically and confirm the patient's pharmacy has it in stock before they leave the hospital. For 300 mg prescriptions, consider routing to a hospital pharmacy or calling ahead.
3. Recommend 90-day mail-order fills: A 90-day supply from a mail-order pharmacy ensures patients have a buffer and reduces the frequency of refills — a key adherence lever.
4. Offer medfinder as a patient resource: medfinder calls pharmacies on behalf of patients to locate their medication — reducing the burden on your office from follow-up calls and reducing the risk that patients quietly stop therapy because they couldn't find the drug.

Learn how medfinder for providers can help your practice reduce therapy gaps for cardiac patients.

Also see: How to Help Your Patients Find Plavix in Stock: A Provider's Guide for more actionable scripts and patient-facing resources.